Vadim Koshkin, MD
Dr. Vadim Koshkin is a genitourinary medical oncologist at the University of California San Francisco where he leads the bladder cancer clinical program in medical oncology. He completed his medical degree at the University of Chicago Pritzker School of Medicine, internal medicine training at the University of Michigan and fellowship in medical oncology at the Cleveland Clinic, and his interests are focused in clinical and translational research of bladder and prostate cancer.
Articles by Vadim Koshkin, MD
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
In the final part of this roundtable, Drs. Koshkin and Grivas discuss the use of EV/pembro and which patients are eligible.
In part five of this roundtable, the panelists explore the use of ctDNA in the TOMBOLA and IMvigor011 trials.
In the fourth part of this roundtable series, the panelists discuss recent updates on bladder-sparing treatments.
In part 3 of this roundtable, the NIAGARA trial is discussed, along with cisplatin regimens and the potential of durvalumab.
In the second part of this roundtable, new trials including VOLGA and EV-304 are analyzed.
In part 1, the panelists examine the evolving treatment landscape of MIBC and NMIBC, including discussion on new trials.
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Drs. Kyriakopoulos and Koshkin break down the CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group.
Drs. Koshkin and Nizam discuss the trastuzumab deruxtecan FDA approval and the DESTINY-PanTumor02 clinical trial.
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
The impact of squamous and other histologies on outcomes with EV are dissected.
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
The panel concludes with their forward-thinking thoughts on the impending direction of urothelial carcinoma treatment.
The panel considered the latest available data pertaining to EV, atezolizumab, erdafitinib, and other therapy options.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.